Inhibition of insulin‐like growth factor‐1 receptor enhances eribulin‐induced DNA damage in colorectal cancer

por Yoshihiro, Tomoyasu, Ariyama, Hiroshi, Yamaguchi, Kyoko, Imajima, Takashi, Yamaga, Satoru, Tsuchihashi, Kenji, Isobe, Taichi, Kusaba, Hitoshi, Akashi, Koichi, Baba, Eishi
Publicado 2022

Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin

por Tsuchihashi, Kenji, Kusaba, Hitoshi, Yoshihiro, Tomoyasu, Fujiwara, Toshifumi, Setsu, Nokitaka, Endo, Makoto, Matsumoto, Yoshihiro, Imajima, Takashi, Shinohara, Yudai, Ito, Mamoru, Yamaga, Satoru, Tanoue, Kenro, Arimizu, Kohei, Ohmura, Hirofumi, Hanamura, Fumiyasu, Yamaguchi, Kyoko, Isobe, Taichi, Ariyama, Hiroshi, Nakashima, Yasuharu, Akashi, Koichi, Baba, Eishi
Publicado 2020